Ownership
Private
Employees
~10
Therapeutic Areas
Immunology
Stage
Phase 1
Modalities
Protein therapeuticsOther

Serenity Bioworks General Information

Lead therapeutic SER-101 has shown preservation of kidney function in lupus mouse model and demonstrated safety in Phase I/IIa clinical trial

Contact Information

Website
Primary Industry
[ "Biotech", "Pharma" ]
Corporate Office
Kitchener, Ontario
Canada

Drug Pipeline

SER-101
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Serenity Bioworks's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Serenity Bioworks Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Serenity Bioworks's complete valuation and funding history, request access »

Serenity Bioworks Investors

IndieBio accelerator program
Investor Type: Venture Capital
Holding: Minority